View Older Stories View More Recent Stories
-
Roth Remains Positive on VBL Therapeutics (VBLT) as VB-111 Phase 3 in rGBM Commences
-
Palatin (PTN) 'Sitting Pretty' After Valeant/Sprout Deal - Roth Capital
-
Palatin's (PTN) BMT Thesis Improves with Recent Sprout Pharma News - Roth Capital (VRX)
-
xG Technology, Inc. Announces Closing of Public Offering
-
Flibanserin Approval Seen as Positive Read-Thru for Sarepta Therapeutics (SRPT), Others - Roth Capital
-
Roth Capital Raises Price target on Energy Focus (EFOI) to $23 Following Recent Volatility
-
Roth Lifts PT on Energy Focus (EFOI) to $23; No Longer Overlooked in Broader Lighting Segment
-
Roth Capital Cuts Price Target on Energy Fuels (UUUU) Following 2Q15 Results
-
Telesta Therapeutics Closes US$28.6 Million Private Placement
-
Palatin Technologies' (PTN) BMT Has Advantages Over Flibanserin, Says Roth
-
Roth Capital Trims PT on Trina Solar (TSL) to $15; China Market Weakness Offsetting Module Strength
-
Roth Capital Trims PT on Canadian Solar (CSIQ) Following Q2 Results, Outlook; Notes Yieldco Remains 'on Track'
-
Roth Capital Affirms Omeros (OMER) at 'Buy' Following Quantified OMS721 Data; Longer-Term Needed for Soliris Comparison
-
Roth Capital Cuts Price Target on Marathon Patent Group (MARA) Following 2Q EPS Miss
-
Roth Capital Reiterates Buy on Quicklogic Corp (QUIK) Seeing Design Wins on Wearables
-
Revel Systems, POS Industry Leader, Extends its Series C to $110 Million to Expand its Industry Leadership
-
Roth Capital Remains Cautiously Optimistic on Spectrum Pharma (SPPI) Following Apaziquone Phase 3 SPA Agreement
-
GPM Reminds Investors of the Upcoming Deadline in the Class Action on Behalf of Iconix Brand Group, Inc. Investors
-
Roth Capital Positive on BioLineRx (BLRX) Following BL-8040 Phase 2b Initiation
-
Roth Affirms Clean Diesel Tech (CDTI) at 'Buy'; Still Sees Cash Shortfall in Early-FY16
-
Marathon Patent Group and Uniloc Agree to Merge
-
xG Technology (XGTI) Prices Class A, B Units Public Offering
-
xG Technology, Inc. Announces Pricing of Public Offering
-
Alcobra Ltd (ADHD) PT Raised to $16 at Roth Capital
-
Unusual 11 Mid-Day Movers 8/13: (CAPN) (PLNR) (OHGI) Higher; (BGMD) (MXPT) (LLNW) Lower
-
Streetinsider.com's Hot Lunchtime Reads 8/13: (QIHU) (AAPL) (OKE) (KERX)
-
ImmunoCellular (IMUC) SPA from FDA 'Significant', Roth Capital Says
-
Roth Capital Cuts Price Target on Ring Energy (REI) Following 2Q15
-
Notable Mergers and Acquisitions 8/13: (ECL)/(SWSH) (HMLP) (RHHBY) (FLO) (PLNR)
-
Pre-Open Stock Movers 08/13: (PLNR) (SUNE) (CSCO) Higher; (BGMD) (SHAK) (KSS) Lower (more...)
-
BG Medicine (BGMD) Prices Series A, B Units Offering at $1/Unit
-
BG Medicine Prices Underwritten Public Offering
-
BG Medicine Prices Underwritten Public Offering
-
Roth Capital Raises Price Target on SolarEdge Technologies (SEDG) Following EPS Beat
-
Leyard Optoelectronic to Acquire Planar Systems (PLNR) for $6.58/Share
-
Planar Agrees to Be Acquired by Leyard for $6.58 Per Share
-
BG Medicine (BGMD) Reports Underwritten Offering
-
BG Medicine Announces Proposed Underwritten Public Offering
-
BG Medicine Announces Proposed Underwritten Public Offering
-
Buy bluebird bio (BLUE) on Weakness Related to GBT IPO, Roth Capital Says
-
Roth Capital Cuts Price target to $35 on Daqo New Energy (DQ) Following 2Q15
-
Roth Capital Trims PT on JA Solar (JASO) to $8 Following Weak Q3 Guide
-
Nuverra Environmental Solutions (NES) Likely to See Crude Oil Headwinds in H215; Roth Affirms at 'Neutral'
-
Supermicro® Announces August and September 2015 Investor Conference Schedule
-
Roth Capital Raises Price on ICU Medical (ICUI) to $124 Following 2Q EPS Beat and Raise
-
Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on Weakness
-
Roth Capital Positive on Rexahn Pharma (RNN) Following Q2 Report; Upcoming Supinoxin, RX-3117 Phase 1 Data is Key
-
TG Therapeutics (TGTX) Continuing to Drive on All Cylinders; Roth Affirms 'Focus Pick' Rating
-
Roth Capital Cuts Price Target on Eco-stim Energy Solutions (ESES) to $7 Following 11c EPS Miss
-
InSite Vision Receives Unsolicited Proposal from a Multi-National Pharmaceutical Company

